Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO) and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on Monday 20 June 2011.
Macular oedema (retinal vein occlusion) - dexamethasone: final appraisal determination document
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Consultee and commentator comments on the ACD
Comments on the ACD received from the public through the NICE website
Additional ERG critique post ACD by Aberdeen HTA Group
This page was last updated: 10 June 2011